Unspecified Adult Solid Tumor, Protocol SpecificNCT01828775
Palliative Care Intervention in Improving Quality of Life, Psychological Distress, and Communication in Patients With Solid Tumors Receiving Treatment
A study testing palliative care, quality-of-life assessment and survey administration in people with Unspecified Adult Solid Tumor, Protocol Specific, run by City of Hope Medical Center at 2 sites in United States.
Trial summary
This pilot randomized clinical trial studies palliative care intervention in improving quality of life, psychological distress, and communication in patients with solid tumors receiving treatment on phase I trials. Read more about this study
- Who is it for?
- Ages 21 years and older
- Conditions the study is for
- Unspecified Adult Solid Tumor, Protocol Specific
- What is being tested?
- palliative care, quality-of-life assessment and survey administration
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 480 participants
- Where
- 2 sitesUnited States
- Study dates
- 17 Sep 2014to 18 May 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients diagnosed with solid tumors who are eligible for participation in Phase I clinical trials of investigational cancer therapies
- Patients who have signed an informed consent for participation in Phase I clinical trials
- Able to read or understand English-this is included because the intervention and study materials (including outcome measures) are only in English
- Ability to read and/or understand the study protocol requirements, and provide written informed consent
Who cannot join
- Patients diagnosed with hematologic (as a population distinct from solid tumors and different trials) cancers.
Trial locations and contacts
2 sites in 1 country.
United States2 sites
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital
Baltimore, Maryland, 21231
City of Hope Medical Center
Duarte, California, 91010
About this study
Official title: Integration of Palliative Care for Cancer Patients on Phase I Trials
This pilot randomized clinical trial studies palliative care intervention in improving quality of life, psychological distress, and communication in patients with solid tumors receiving treatment on phase I trials. Cancer patients experience many symptoms related to treatment and the cancer itself that can be distressing and impact quality of life. Palliative care focuses on managing these symptoms and may help patients with solid tumors live more comfortably.
Read the detailed description
PRIMARY OBJECTIVES:
- Test the effects of a palliative care intervention (PCI) on patients' quality of life (QOL), psychological distress and satisfaction with communication, comparing the experimental versus control groups.
II. Test the effects of a PCI on patients' symptom intensity and symptom interference with daily activities, comparing the experimental versus control groups.
III. Test the effects of a PCI on patients' hospital and palliative care resource utilization and clinical trial retention rates, comparing the experimental versus control groups.
IV. Test the effects of the timing of PCI initiation (early versus delayed) on patient outcomes, comparing the experimental versus control groups.
- Describe patients' satisfaction with the PCI.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive part I of the PCI comprising quantitative surveys, comprehensive palliative care assessment by the Research Nurses, and goals of care discussions beginning prior to administration of the first dose of phase I treatment. Patients then receive part II of the PCI comprising recommendations from the interdisciplinary team, patient educational sessions, and supportive care referrals following the first dose of phase I treatment and is completed within one month of the first treatment.
ARM II: Patients receive usual care until 12 weeks post-treatment initiation. Patients then receive both part I and II of the PCI.
After completion of study, patients are followed up for 5 years.
- Being tested
- palliative care, quality-of-life assessment, survey administration
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
palliative careOther
Receive early PCI
palliative careOther
Receive delayed PCI
quality-of-life assessmentProcedure or surgery
Also called quality of life assessment
Ancillary studies
survey administrationOther
Ancillary studies
| Study group | Role | What they receive |
|---|---|---|
| Arm I (early PCI) | Experimental | Patients receive part I of the PCI comprising quantitative surveys, comprehensive palliative care assessment by the Research Nurses, and goals of care discussions beginning prior to administration of the first dose of phase I treatment. Patients then receive part II of the PCI comprising recommendations from the interdisciplinary team, patient educational sessions, and supportive care referrals following the first dose of phase I treatment and is completed within one month of the first treatment. Receives: Other: palliative care; Procedure: quality-of-life assessment; Other: survey administration |
| Arm II (delayed PCI) | Experimental | Patients receive usual care until 12 weeks post-treatment initiation. Patients then receive both part I and II of the PCI. Receives: Other: palliative care; Procedure: quality-of-life assessment; Other: survey administration |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in overall QOL scores, assessed by the Functional Assessment of Cancer Therapy-General (FACT-G) and Functional Assessment of Chronic Illness Therapy-Spirituality (FACIT-Sp)
To control for inflation of experimentwise error caused by analyzing four different QOL subscales, alpha will be set to .01. A 2x2 multiply repeated measures ANCOVA (in which the within groups variables are QOL subscale scores at 4 and 12 weeks, the between groups measure is treatment group (control vs. PCI), and the covariate is baseline QOL) might be employed if the correlation between the four FACT-G subscale scores are high enough to warrant such an analysis. The overall QOL score derived from the FACT-G will be tested individually using alpha=.05.
If subscale correlations are not high, outcome will be analyzed using four 2x2 repeated measures ANCOVAs in which the within groups variable is each QOL subscale, the between groups measure is group (PCI vs. control), and the covariate is the appropriate baseline QOL subscale (Physical well-being, emotional well-being, social well-being, and functional well-being).
Measured: Baseline to 12 weeks
Change in psychological distress, assessed using the Psychological Distress Thermometer
Analyzed using a 2x2 repeated measures ANCOVA to test for differences in psychological distress (Psychological Distress Thermometer scores), at 4 and 12-week between the PCI and control groups, controlling for baseline psychological distress.
Measured: Baseline to 12 weeks
Satisfaction with communication, measured by the Family Satisfaction with Advanced Cancer Care (FAMCARE)
Analyzed using a 2x2 repeated measures ANCOVA to test for differences in satisfaction (Family Satisfaction with Advanced Cancer Care scores), at 4 and 12-week between the PCI and control groups, controlling for baseline satisfaction.
Measured: 12 weeks
Patients' symptom intensity and symptom interference with daily activities
Analyzed using a 2x2 repeated measures ANCOVA to test for differences in symptom intensity and symptom interference with daily activities (using Psychological Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO - CTCAE) scores), at 4 and 12-week between the PCI and control groups, controlling for baseline symptom intensity and symptom interference.
Measured: 12 weeks
Total numbers of supportive care referrals (social work, dietitian, chaplaincy, psychologist/psychiatrist)
Contingency table analysis and the chi square statistic will be used to examine the association between group and referral to various support services. In addition, total number of referrals will be counted and an independent student's t-test will be used to test for significant differences in number of total referrals between groups.
Measured: 12 weeks
Total number of unscheduled outpatient encounters and inpatient admissions
Total number of encounters and admissions will be counted and an independent student's t-test for each variable will be used to test for significant differences in number of total encounters and number of unscheduled admissions between groups.
Measured: 12 weeks
Total number of hospice referrals
Contingency table analysis with the chi square statistic to examine the association between group and hospice referral.
Measured: 12 weeks
Retention on the Phase I trial
Contingency table analysis with the chi square statistic to examine the association between group and Phase I trial retention.
Measured: 12 weeks
Patient satisfaction with the PCI
Descriptive statistics and comparisons between the two groups will be conducted for overall satisfaction with intervention content and timing of the intervention.
Measured: 12 weeks
Secondary outcomes (12)
Change in overall QOL scores, assessed by FACT-G and FACIT-Sp
To control for inflation of experimentwise error caused by analyzing four different QOL subscales, alpha will be set to .01. A 2x2 multiply repeated measures ANCOVA (in which the within groups variables are QOL subscale scores at 4 weeks, the between groups measure is treatment group (control vs. PCI), and the covariate is baseline QOL) might be employed if the correlation between the four FACT-G subscale scores are high enough to warrant such an analysis. The overall QOL score derived from the FACT-G will be tested individually using alpha=.05.
If subscale correlations are not high, outcome will be analyzed using four 2x2 repeated measures ANCOVAs in which the within groups variable is each QOL subscale, the between groups measure is group (PCI vs. control), and the covariate is the appropriate baseline QOL subscale (Physical well-being, emotional well-being, social well-being, and functional well-being).
Measured: Baseline to 4 weeks
Change in overall QOL scores, assessed by FACT-G and FACIT-Sp
To control for inflation of experimentwise error caused by analyzing four different QOL subscales, alpha will be set to .01. A 2x2 multiply repeated measures ANCOVA (in which the within groups variables are QOL subscale scores at 24 weeks, the between groups measure is treatment group (control vs. PCI), and the covariate is baseline QOL) might be employed if the correlation between the four FACT-G subscale scores are high enough to warrant such an analysis. The overall QOL score derived from the FACT-G will be tested individually using alpha=.05.
If subscale correlations are not high, outcome will be analyzed using four 2x2 repeated measures ANCOVAs in which the within groups variable is each QOL subscale, the between groups measure is group (PCI vs. control), and the covariate is the appropriate baseline QOL subscale (Physical well-being, emotional well-being, social well-being, and functional well-being).
Measured: Baseline to 24 weeks
Change in psychological distress, assessed using the Psychological Distress Thermometer
Analyzed using a 2x2 repeated measures ANCOVA to test for differences in psychological distress (Psychological Distress Thermometer scores), at 4 weeks, between the PCI and control groups, controlling for baseline psychological distress.
Measured: Baseline to 4 weeks
Change in psychological distress, assessed using the Psychological Distress Thermometer
Analyzed using a 2x2 repeated measures ANCOVA to test for differences in psychological distress (Psychological Distress Thermometer scores), at 24 weeks, between the PCI and control groups, controlling for baseline psychological distress.
Measured: Baseline to 24 weeks
Satisfaction with communication, measured by FAMCARE
Analyzed using a 2x2 repeated measures ANCOVA to test for differences in satisfaction (Family Satisfaction with Advanced Cancer Care scores), at 4 weeks, between the PCI and control groups, controlling for baseline satisfaction.
Measured: 4 weeks
Satisfaction with communication, measured by FAMCARE
Analyzed using a 2x2 repeated measures ANCOVA to test for differences in satisfaction (Family Satisfaction with Advanced Cancer Care scores), up to 24 weeks, between the PCI and control groups, controlling for baseline satisfaction.
Measured: Up to 24 weeks
Patients' symptom intensity and symptom interference with daily activities
Analyzed using a 2x2 repeated measures ANCOVA to test for differences in symptom intensity and symptom interference with daily activities (Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO - CTCAE) scores), up to 24 weeks, between the PCI and control groups, controlling for baseline satisfaction.
Measured: Up to 24 weeks
Total numbers of supportive care referrals (social work, dietitian, chaplaincy, psychologist/psychiatrist)
Contingency table analysis and the chi square statistic will be used to examine the association between group and referral to various support services for up to 24 weeks. In addition, total number of referrals will be counted and an independent student's t-test will be used to test for significant differences in number of total referrals between groups.
Measured: Up to 24 weeks
Total number of unscheduled outpatient encounters and inpatient admissions
Total number of encounters and admissions will be counted and an independent student's t-test for each variable will be used to test for significant differences in number of total encounters and number of unscheduled admissions between groups for up to 24 weeks.
Measured: Up to 24 weeks
Total number of hospice referrals
Contingency table analysis with the chi square statistic to examine the association between group and hospice referral for up to 24 weeks.
Measured: Up to 24 weeks
Retention on the Phase I trial
Contingency table analysis with the chi square statistic to examine the association between group and Phase I trial retention for up to 24 weeks.
Measured: Up to 24 weeks
Patient satisfaction with the PCI
Descriptive statistics and comparisons between the two groups will be conducted for overall satisfaction with intervention content and timing of the intervention for up to 24 weeks.
Measured: Up to 24 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Apr 2013 (estimated)
- Study start17 Sep 2014
- Primary completion18 May 2020
- Study completion18 May 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Unspecified Adult Solid Tumor, Protocol SpecificStudies of the same condition, open and under way.
- More trials run by City of Hope Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 480 participants (actual)
Sponsor and investigators
- Lead sponsor
- City of Hope Medical Center
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Betty Ferrell, Principal investigator, City of Hope Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01828775
- Sponsor's protocol ID
- 13193
- Other IDs
- NCI-2013-00731, 1R01CA177562-01A1
- Status last verified
- Oct 2026
- First submitted
- 2 Apr 2013
- Last updated
- 26 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 26 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Integration of Palliative Care for Cancer Patients on Phase I Trials
- ClinicalTrials.gov ID
- NCT01828775
- Acronym / sponsor ID
- 13193
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 480 participants (actual)
- Lead sponsor
- City of Hope Medical CenterUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Study start
- 17 Sep 2014 (actual)
- Primary completion
- 18 May 2020 (actual)
- Study completion
- 18 May 2020 (actual)
- First posted
- 11 Apr 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This pilot randomized clinical trial studies palliative care intervention in improving quality of life, psychological distress, and communication in patients with solid tumors receiving treatment on phase I trials. Cancer patients experience many symptoms related to treatment and the cancer itself that can be distressing and impact quality of life. Palliative care focuses on managing these symptoms and may help patients with solid tumors live more comfortably.
Detailed description
PRIMARY OBJECTIVES:
- Test the effects of a palliative care intervention (PCI) on patients' quality of life (QOL), psychological distress and satisfaction with communication, comparing the experimental versus control groups.
II. Test the effects of a PCI on patients' symptom intensity and symptom interference with daily activities, comparing the experimental versus control groups.
III. Test the effects of a PCI on patients' hospital and palliative care resource utilization and clinical trial retention rates, comparing the experimental versus control groups.
IV. Test the effects of the timing of PCI initiation (early versus delayed) on patient outcomes, comparing the experimental versus control groups.
- Describe patients' satisfaction with the PCI.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive part I of the PCI comprising quantitative surveys, comprehensive palliative care assessment by the Research Nurses, and goals of care discussions beginning prior to administration of the first dose of phase I treatment. Patients then receive part II of the PCI comprising recommendations from the interdisciplinary team, patient educational sessions, and supportive care referrals following the first dose of phase I treatment and is completed within one month of the first treatment.
ARM II: Patients receive usual care until 12 weeks post-treatment initiation. Patients then receive both part I and II of the PCI.
After completion of study, patients are followed up for 5 years.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Arm I (early PCI) | Experimental | Other: palliative care, Procedure: quality-of-life assessment, Other: survey administrationPatients receive part I of the PCI comprising quantitative surveys, comprehensive palliative care assessment by the Research Nurses, and goals of care discussions beginning prior to administration of the first dose of phase I treatment. Patients then receive part II of the PCI comprising recommendations from the interdisciplinary team, patient educational sessions, and supportive care referrals following the first dose of phase I treatment and is completed within one month of the first treatment. |
| Arm II (delayed PCI) | Experimental | Other: palliative care, Procedure: quality-of-life assessment, Other: survey administrationPatients receive usual care until 12 weeks post-treatment initiation. Patients then receive both part I and II of the PCI. |
Who may qualify
- Ages
- 21 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Patients diagnosed with solid tumors who are eligible for participation in Phase I clinical trials of investigational cancer therapies
- Patients who have signed an informed consent for participation in Phase I clinical trials
- Able to read or understand English-this is included because the intervention and study materials (including outcome measures) are only in English
- Ability to read and/or understand the study protocol requirements, and provide written informed consent
Key exclusion criteria (1 listed)
- Patients diagnosed with hematologic (as a population distinct from solid tumors and different trials) cancers.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| palliative careReceive early PCI | Other | Arm I (early PCI) |
| palliative careReceive delayed PCI | Other | Arm II (delayed PCI) |
| quality-of-life assessmentAlso: quality of life assessmentAncillary studies | Procedure or surgery | Arm I (early PCI), Arm II (delayed PCI) |
| survey administrationAncillary studies | Other | Arm I (early PCI), Arm II (delayed PCI) |
Primary outcome
Change in overall QOL scores, assessed by the Functional Assessment of Cancer Therapy-General (FACT-G) and Functional Assessment of Chronic Illness Therapy-Spirituality (FACIT-Sp)
Time frame: Baseline to 12 weeks
To control for inflation of experimentwise error caused by analyzing four different QOL subscales, alpha will be set to .01. A 2x2 multiply repeated measures ANCOVA (in which the within groups variables are QOL subscale scores at 4 and 12 weeks, the between groups measure is treatment group (control vs. PCI), and the covariate is baseline QOL) might be employed if the correlation between the four FACT-G subscale scores are high enough to warrant such an analysis. The overall QOL score derived from the FACT-G will be tested individually using alpha=.05. If subscale correlations are not high, outcome will be analyzed using four 2x2 repeated measures ANCOVAs in which the within groups variable is each QOL subscale, the between groups measure is group (PCI vs. control), and the covariate is the appropriate baseline QOL subscale (Physical well-being, emotional well-being, social well-being, and functional well-being).
Change in psychological distress, assessed using the Psychological Distress Thermometer
Time frame: Baseline to 12 weeks
Analyzed using a 2x2 repeated measures ANCOVA to test for differences in psychological distress (Psychological Distress Thermometer scores), at 4 and 12-week between the PCI and control groups, controlling for baseline psychological distress.
Satisfaction with communication, measured by the Family Satisfaction with Advanced Cancer Care (FAMCARE)
Time frame: 12 weeks
Analyzed using a 2x2 repeated measures ANCOVA to test for differences in satisfaction (Family Satisfaction with Advanced Cancer Care scores), at 4 and 12-week between the PCI and control groups, controlling for baseline satisfaction.
Patients' symptom intensity and symptom interference with daily activities
Time frame: 12 weeks
Analyzed using a 2x2 repeated measures ANCOVA to test for differences in symptom intensity and symptom interference with daily activities (using Psychological Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO - CTCAE) scores), at 4 and 12-week between the PCI and control groups, controlling for baseline symptom intensity and symptom interference.
Total numbers of supportive care referrals (social work, dietitian, chaplaincy, psychologist/psychiatrist)
Time frame: 12 weeks
Contingency table analysis and the chi square statistic will be used to examine the association between group and referral to various support services. In addition, total number of referrals will be counted and an independent student's t-test will be used to test for significant differences in number of total referrals between groups.
Total number of unscheduled outpatient encounters and inpatient admissions
Time frame: 12 weeks
Total number of encounters and admissions will be counted and an independent student's t-test for each variable will be used to test for significant differences in number of total encounters and number of unscheduled admissions between groups.
Total number of hospice referrals
Time frame: 12 weeks
Contingency table analysis with the chi square statistic to examine the association between group and hospice referral.
Retention on the Phase I trial
Time frame: 12 weeks
Contingency table analysis with the chi square statistic to examine the association between group and Phase I trial retention.
Patient satisfaction with the PCI
Time frame: 12 weeks
Descriptive statistics and comparisons between the two groups will be conducted for overall satisfaction with intervention content and timing of the intervention.
12 secondary outcomes
Change in overall QOL scores, assessed by FACT-G and FACIT-Sp
Time frame: Baseline to 4 weeks
Change in overall QOL scores, assessed by FACT-G and FACIT-Sp
Time frame: Baseline to 24 weeks
Change in psychological distress, assessed using the Psychological Distress Thermometer
Time frame: Baseline to 4 weeks
Change in psychological distress, assessed using the Psychological Distress Thermometer
Time frame: Baseline to 24 weeks
Satisfaction with communication, measured by FAMCARE
Time frame: 4 weeks
Satisfaction with communication, measured by FAMCARE
Time frame: Up to 24 weeks
Patients' symptom intensity and symptom interference with daily activities
Time frame: Up to 24 weeks
Total numbers of supportive care referrals (social work, dietitian, chaplaincy, psychologist/psychiatrist)
Time frame: Up to 24 weeks
Total number of unscheduled outpatient encounters and inpatient admissions
Time frame: Up to 24 weeks
Total number of hospice referrals
Time frame: Up to 24 weeks
Retention on the Phase I trial
Time frame: Up to 24 weeks
Patient satisfaction with the PCI
Time frame: Up to 24 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Oct 2026.
Related trials for Unspecified Adult Solid Tumor, Protocol Specific
Active, not recruitingPhase 1
RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists
Unspecified Adult Solid Tumor, Protocol Specific
Active, not recruiting
Assessment Tool for Older Patients With Cancer
Cognitive/Functional Effects, Psychosocial Effects of Cancer and Its Treatment
Active, not recruiting
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
Breast Cancer, Colon Cancer
Recruiting
Copenhagen Prospective Personalized Oncology (CoPPO)
Unspecified Adult Solid Tumor, Protocol Specific
Active, not recruiting
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Betty Ferrell principal investigator
City of Hope Medical Center
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing palliative care, quality-of-life assessment and survey administration in people with Unspecified Adult Solid Tumor, Protocol Specific, run by City of Hope Medical Center at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in overall QOL scores, assessed by the Functional Assessment of Cancer Therapy-General (FACT-G) and Functional Assessment of Chronic Illness Therapy-Spirituality (FACIT-Sp) (time frame: Baseline to 12 weeks). The study lists 9 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Oct 2026.